The sales of nervous system medicines in Canada are projected to show a gradual decline from 2024 to 2028, starting at 17.2% of total sales in 2024 and decreasing to 16.5% by 2028. Compared to the 2023 figure, actual sales data was indicative of a similar trend, with annual reductions noted. The compounded annual growth rate (CAGR) over the five years is negative, suggesting a consistent downward trajectory.
Future trends to watch for include advancements in treatment efficacy and innovation, potential new entrants disrupting the market, pricing pressures, and changes in healthcare policies impacting prescriptions and sales dynamics. Monitoring these factors could provide insights into potential shifts or opportunities in the market landscape.
